Effect of Sodium Glucose co Transporter 2 Inhibitor ( SGLT2) on Proteinuria in Diabetic Patients

Last updated: April 18, 2020
Sponsor: Nahla H Tohami
Overall Status: Active - Recruiting

Phase

4

Condition

Proteinuria

Treatment

N/A

Clinical Study ID

NCT03573102
SGLT2 antiproteinuric effect
  • Ages > 18
  • All Genders

Study Summary

Diabetes Mellitus is the leading cause of end stage renal disease. As proven by many studies , controlling proteinuria can delay the progression to end stage renal disease.This work will study the effect of sodium glucose co transporter 2 inhibitor , a new antihyperglycemic drug , on proteinuria and to compare its effect with the effect of classic antiproteinuric drugs as angiotensin converting enzyme inhibitor , aspirin and statins.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • adult patients with type 2 diabetes.

  • controlled diabetes.

  • patients with proteinuria

Exclusion

Exclusion Criteria:

  • patients with proteinuria due to other disease.

  • patients with HbA1c >8%.

  • patients with uncontrolled hypertension.

  • patients with chronic liver disease.

  • patients with type 1 diabetes .

  • patients already on the same drug ( dapagliflozine).

  • patients with raised serum creatinine.

Study Design

Total Participants: 60
Study Start date:
June 20, 2018
Estimated Completion Date:
July 31, 2020

Study Description

Diabetic nephropathy involves progressive stages including glomerular hyperfilteration , microalbuminuria , overt proteinuria and a decline in glomerular filteration rate leading to end stage renal disease.

Despite all the available interventions available for diabetic patients including tight glycemic control , and blood pressure control , using angiotensin converting enzyme inhibitors, angiotensin II receptor antagonist renal disease remains prevalent and progress in these patients.

The newer therapy of diabetes is the use of sodium glucose cotransporter 2 inhibitor as it has the potential of renoprotection in patients with diabetic nephropathy just as ACEI and ARBS to reduce glomerular hyperfilteration .This action may reduce albuminuria.

Connect with a study center

  • Ain Shams University Hospitals

    Cairo, 002
    Egypt

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.